The Role of Business Development in Changing Global Times

Size: px
Start display at page:

Download "The Role of Business Development in Changing Global Times"

Transcription

1 XIII International Pharma Licensing Symposium The Role of Business Development in Changing Global Times Thursday 28th & Friday 29th September 2017 Event Highlights Welcome Networking Reception NEW Partnering System to Arrange Your Own Private Meeting Schedule Specific Private Meeting Area 6 Presentation Sessions, including OTC, Digital Technology and IP & Market Access Networking Reception and Gala Dinner at Casino de Madrid Access to Copies of Authorised Presentation Post-Event Opportunity to Network with BD Colleagues from Across Europe MADRID

2 Wednesday, 27th September Pre-Arranged One-to-One Meetings Welcome Drinks Reception Thursday, 28th September Registration SESSION External Factors Impacting the Pharmaceutical Industry Introduction & Keynote Presentation Juan López-Belmonte, Vice President, Farmaindustria & CEO, Laboratorios Rovi Speaking from both an industry and business perspective, Juan López-Belmonte will be setting the scene identfying the key challenges emerging from the current political climate, with a focus on the economic and business implictaions for pharmaceutical deal making Industry Drivers, Trends, Analysis and Forecasts Antonio Iervolino, Head of Forecasting, Evaluate Sharing their insightful data and industry analysis, Evaluate are back by popular demand to identify the key trends evident in deals quantifying the impact on pharma business from the changing macro deal conditions Brexit - Impact on Pharmaceutical Industry? European View: Impact on Strategies & UK View: Situation Post Brexit European View - Sergio Napolitano, Legal, Trade and Public Affairs Director, Medicines for Europe UK View - Jo Pisani, Partner, UK Pharma and Lifesciences Consulting Leader, PwC Strategy& Capturing and reflecting on the latest in developments in the Brexit negotiations, our speakers will comment on the key issues from both sides in the negotiation providing the view from the European and UK perspectives Break SESSION The Impact of Digital Technology Case Study Sanofi & Voluntis Pierre Leurent, Voluntis In March Sanofi and Voluntis announced the original 2011 alliance to provide an app for assessing basal insulin was expanded. Pierre Leurent will be commenting on key features of this successful deal Technology Companies Stepping into Digital Technologies Néstor Sanchez, Digital Transformation Manager, Indra With a wealth of experience in the development of healthcare information systems, Indra will review the impact of the transformations offered by digital technologies Impact of General Data Protection Regulation (GDPR) Christoph Balduck, Managing Partner, Data Trust Associates This presentation will help healthcare companies to identify what challenges companies are facing in relation to privacy and data management strategies and way forward, including recommendations and best practices.

3 Lunch SESSION The Role of Business Development Panel Discussion - Business Development and Alliance Management Good Partnering Practices (GPP) conceived under the leadership of Swiss HLG Chair Anthony A. Hörning, Strategic Transactions Advisory How do BD leaders see the impact of Good Partnering Practices in their organisations? Panel Laurence de Schoulepnikoff, Head of Strategy, Transaction and Legal Jörg Mayer, Director Business Development Europe, LTS Lohmann Henning Mennenöh, Weitnauer Advokaten Pre-Arranged One-to-One meetings Gala Dinner

4 Friday, 29th September SESSION The Increasing Importance of the OTC and Other Business Areas Case Study: Nestlé Health Science - Where Nutrition becomes Therapy Kim Bill, Vice President, Global Business Development & Licensing, Nestlé Health Science Identifying new business opportunities for growth in consumer healthcare markets Emerging Trends in OTC & Why Big Pharma Should Play There Nicholas Hall, Chairman & CEO, Nicholas Hall Group of Companies Nicholas Hall will focus on the key opportunities arising in the OTC arena and the role major pharma play Strategy Options for OTC in Emerging Markets and How to Enter the Best Markets Reiner Christensen, CEO and Co-Founder, Chameleon Pharma Consulting Group Reiner will give his insights on the OTC sector and how pharma companies can enter countries providing the best value Break SESSION Risk or Opportunity? IP & Market Access IP Management/Protection Livia Villa, European Patent Attorney, ADV IP Livia Villa will review the latest developments in IP in Europe including updates on SPC s Market Access European Trends Professor Mondher Toumi, CEO, Creativ-Ceutical Critical to successful BD, Professor Toumi will consider recent decisions and issues arising in securing prices and gaining effective market access in Europe Break SESSION Financial Evaluation & Business Models From Valuation to Assets or From Assets to Valuation? Zaki Sellam, Managing Director, ESN Life Sciences This session will aim at not only using a simplified & elaborated rnpv model but also at understanding various asset features which are usually underestimated for a valuation Business Models Paul Pay, Chief Business Development Officer, Norgine With business deals becoming increasingly creative, this presentation will review some successful example of innovative deal structures Lunch and close

5 XIII International Pharma Licensing Symposium NH Collection Eurobuilding Hotel, Madrid Thursday 28 th & Friday 29 th September 2017 To register for the XIII IPLS Meeting, please complete this form and return to NGA using one of the following methods: Post NGA, Millennia House, Kingswood Park, Bonsor Drive, Kingswood, Surrey, KT20 6AY, UK Fax (0) Title Dr / Mr / Mrs / Ms Name Job Title Company Address Country Telephone (general contact and confirmation) (used for delegate contact system) Special Requirements (e.g. dietary, access requirements etc) VAT Number (must be completed to confirm registration) Price 875 Early Payment Discount Rate for payments received by 8 th May ,025 Standard Rate for payments received on or after 9 th May 2017 Accommodation Link to Discounted Accommodation Rates at NH Collection Eurobuilding Hotel, Madrid Payment Payment by Cheque made payable to NGA Ltd at the address above Payment by Bank Transfer Payment by Credit Card details will be sent out with booking confirmation MasterCard or Visa only, complete section below Name of Card Holder Credit Card Number Expiry Date Cardholder Signature Security Code Date The NEW partnering system will be opened at the beginning of June, at which time you will be ed a password to allow you access to your own profile on the partnering system, allowing you to edit your profile and arrange your own meeting schedule Booking Terms & Conditions Fee The attendance fee includes attendance at all sessions noted on the programme, all breaks, lunches and networking events. Please note that for reasons beyond the control of the organising committee it may prove necessary to change or amend the content or timing of the programme without prior warning. Meeting Registration No Shows If having received a confirmed booking to the meeting, individuals who do not attend the meeting without prior notification to NGA in writing, will be liable for the full registration fee. Meeting Cancellations Upon receiving your completed registration form, NGA will issue confirmation details and this booking will then be formally confirmed. Please note that all cancellations will be subject to a 50 administration charge. Delegate substitutions are welcome at any time. Cancellations received in writing after 21 st July 2017 will be subject to 100% cancellation charge unless the place can be re-sold to another delegate. In this case the 50 administration charge will apply. All cancellations must be sent to NGA in writing.